JAK1 and fleck corneal dystrophy: The Janus kinase/signal transducers andactivators of transcription (JAK/STAT) pathways have been reported to feature more prominentlyin patients with perianal FCD.2 We alsodiscussed the Phase 2 DIVERGENCE study that evaluated filgotinib (oral JAK1 inhibitor) for thetreatment of perianal FCD.3